DETROIT – The data from vaccine-maker Pfizer that the Food and Drug Administration will be relying on to make a decision about an Emergency Use Authorization this Thursday was made public on Tuesday. The 92-page document and the FDA’s 53-page briefing document are full of details on who received the vaccine and how effective it was. The summary lays out the demographics for the nearly 38,000 study participants, half of which received the vaccine and half of which receive a placebo. Two doses of the Pfizer-BioNTech vaccine are administered 21 days apart. The primary question was how effectively can the vaccine prevent COVID-19 infection 7 days after the second dose of the vaccine?